The Use of lithium in psychiatric, viral and neurological disorders - a review
DOI:
https://doi.org/10.12775/JEHS.2023.18.01.013Keywords
lithium, bipolar disorder, mania, depression, suicidal risk, side effectsAbstract
Introduction: Lithium is one of the longest used drugs in psychiatry and is currently a mainstay in the long-term prophylaxis of bipolar disorder, preventing recurrent manic and depressive episodes. It also remains an important drug in the treatment of acute episodes of mania and depression. Out of the normothymic drugs, lithium has the greatest effect in preventing suicidal behavior. It also exhibits antiviral activity and in recent years evidence has also accumulated of the drug's neuroprotective properties.
Aim of the study: The aim was to collect and analyze publications on the use of lithium in affective disorders, dementia and viral diseases, as well as its effect on reducing suicidal tendencies.
Materials and Methods: The literature available in the PubMed database was reviewed, using the key words: "lithium"; "bipolar disorder"; "mania", "depression"; "suicidal risk", "side effects".
Results: Chronic use of lithium in patients with bipolar disorder has an effect on preventing recurrence of manic and depressive episodes and can successfully last for 40 years or longer. Studies support the theory that long-term lithium pharmacotherapy has a significant impact on preventing suicidal tendencies among patients with affective disorders. In recent years, the antiviral and neuroprotective properties of the drug have also become known. Despite the rather high risk of overdose, as well as the occurrence of numerous side effects, lithium is still very often used in the treatment of affective disorders due to its high efficacy.
Conclusions: Lithium has been one of the mainstays of psychopharmacology for several decades and is a precursor to mood-stabilizing drugs. In recent years evidence has also been collected for its potential use in non-psychiatric conditions. Conducting further research on lithium will certainly allow for wider use of the drug and a more thorough understanding of its mechanism of action.
References
Schou M. Fifty years of treatments for bipolar disorder: a celebration of John Cade’s discovery. Aust N Z J Psychiatry. 1999;33:S1–122.
Yatham L.N., Kennedy S.H., Parikh S.V., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.
Malhi G.S., Bell E., Boyce P., et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. Bipolar Disord. 2020;22:805–821. doi: 10.1111/bdi.13036.
Bauer M: 70 Years of Research and 50 Years of Lithium linics: From Serendipity to Gold Standard in Mood Disorders. Pharmacopsychiatry 2018; 51:165.
Tondo L, Alda M, Bauer M, et al. ,… for the International Group for Studies of Lithium (IGSLi): Clinical use of lithium salts: Guide for users and prescribers. International Journal of Bipolar Disorders 2019; 7:16.
Shaldubina A., Agam G., Belmaker R.H. The mechanism of lithium action: state of the art., ten years later. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 2001 vol. 25: 855–866.
Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet (2016) 387(10027):1561–72. 10.1016/S0140-6736(15)00241-X.
Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord (2017) 217:266–80. 10.1016/j.jad.2017.03.052.
Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (2013) 346:f3646. 10.1136/bmj.f3646.
Severus E, Taylor MJ, Sauer C, Pfennig A, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord (2014) 2:15. 10.1186/s40345-014-0015-8.
Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry (2014) 1(5):351–9. 10.1016/S2215-0366(14)70314-1.
Kessing LV, Bauer M, Nolen WA, et al. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord (2018) 20:419–31. 10.1111/bdi.12623.
Hayes JF, Marston L, Walters K, et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry (2016) 15(1):53–8. 10.1002/wps.20298.
Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev (2001) 2001(3):CD003013. 10.1002/14651858.CD003013.
Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord (2019) 21(5):394–409. 10.1111/bdi.12805.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013.
Cotovio G, Oliveira-Maia AJ. Functional neuroanatomy of mania. Transl Psychiatry. 2022 Jan 24;12(1):29. doi: 10.1038/s41398-022-01786-4. PMID: 35075120; PMCID: PMC8786958.
Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord. 2017 Aug 1;217:266-280. doi: 10.1016/j.jad.2017.03.052. Epub 2017 Mar 27. PMID: 28437764.
E. Managing Bipolar Disorder in Clinical Practice: Third Edition. Springer Healthcare;
doi:10.1007/978-1-908517-94-4.
Hsu CW, Tsai SY, Tseng PT, et al. Differences in the prophylactic effect of serum lithium levels on depression and mania in bipolar disorder: A dose-response meta-analysis. Eur Neuropsychopharmacol. 2022 May;58:20-29. doi: 10.1016/j.euroneuro.2022.01.112. Epub 2022 Feb 11. PMID: 35158229.
Pacchiarotti I, Anmella G, Colomer L, et al. How to treat mania. Acta Psychiatr Scand. 2020 Sep;142(3):173-192. doi: 10.1111/acps.13209. Epub 2020 Aug 3. PMID: 33460070.
Köhler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry (2014) 47(2):53–9. 10.1055/s-0033-1364004.
McGirr A, Vohringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry (2016) 3(12):1138–46. 10.1016/S2215-0366(16)30264-4.
Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? J Affect Disord (2009) 115(1-2):234–40. 10.1016/j.jad.2008.07.007.
Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry (2010) 71(2):150–62. 10.4088/JCP.08m04995gre.
Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol (2008) 28(2):171–81. 10.1097/JCP.0b013e318166c4e6.
Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord (2018) 20(2):97–170. 10.1111/bdi.12609.
DGBS and DGPPN S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion (2019). [cited 2.0; Available from: www.leitlinie-bipolar.de.
Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 11(2):81–109. 10.3109/15622970903555881.
Torem MS. Beyond lithium: using psychotherapy to reduce suicide risk in bipolar disorder: novel approach teaches patients to “disown” suicidal thoughts, internalize future. Curr Psychiatry. 2011;10(10):39.
Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:36–46.
Terao T, Goto S, Inagaki M, Okamoto Y. Even very low but sustained lithium intake can prevent suicide in the general population? Med Hypotheses. 2009;73(05):811–812.
Lewitzka U, Bauer M. What role does (should) lithium play in suicide treatment/prevention? Psychiatric Times. 2014;31(12):10–13.
Steiner J, Bogerts B, Sarnyai Z, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity. World J Biol Psychiatry. 2012;13(07):482–492.
Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60:77–84.
Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34(04):132–136.
Lewitzka U, Severus E, Bauer R, et al. The suicide prevention effect of lithium: More than 20 years of evidence-a narrative review. Int. J. Bipolar Disord. 2015; 3(1): 32.
Rybakowski J.K., Suwalska A., Hajek T. Clinical perspectives of lithium’s neuroprotective effect. Pharmacopsychiatry. 2018;51:194–199. doi: 10.1055/s-0043-124436.
Hajek T., Bauer M., Simhandl C., et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med. 2014;44:507–517. doi: 10.1017/S0033291713001165.
Chen S., Underwood B.R., Jones P.B., et al. Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study. PLoS Med. 2022;19:e1003941. doi: 10.1371/journal.pmed.1003941.
Kessing L.V., Gerds T.A., Knudsen N.N., et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry. 2017;74:1005–1010. doi: 10.1001/jamapsychiatry.2017.2362.
Fajardo V.A., Fajardo V.A., LeBlanc P.J., et al. Examining the relationship between trace lithium in drinking water and the rising rates of age-adjusted Alzheimer’s disease mortality in Texas. J. Alzheimers Dis. 2018;61:425–434. doi: 10.3233/JAD-170744.
Kessing L.V., Forman J.L., Andersen P.K. Does lithium protect against dementia ? Bipolar Disord. 2010;12:87–94. doi: 10.1111/j.1399-5618.2009.00788.x.
Matsunaga S., Kishi T., Annas P., et al. Lithium as a treatment for Alzheimer’s disease: A systematic review and meta-analysis. J. Alzheimers Dis. 2015;48:403–410. doi: 10.3233/JAD-150437.
Skinner G.R.B., Hartley C., Buchan A., et al. The effect of lithium chloride on the replication of herpes simplex virus. Med. Microbiol. Immunol. 1980;168:258–265. doi: 10.1007/BF02121762.
Rybakowski J.K., Amsterdam J.D. Lithium prophylaxis and recurrent labial herpes infections. Lithium. 1991;2:43–47.
Nowak J.K., Walkowiak J. Lithium and coronaviral infections. A scoping review. F1000Research. 2020;9:93. doi: 10.12688/f1000research.22299.2.
Murru A., Manchia M., Hajek T., et al. Lithium’s antiviral effects: A potential drug for COVID-19 disease? Int. J. Bipolar Disord. 2020;8:21. doi: 10.1186/s40345-020-00191-4.
De Picker L.J., Leboyer M., Geddes J.R., et al. Association between serum lithium level and incidence of COVID-19 infection. Br. J. Psychiatry. 2022;221:425–427. doi: 10.1192/bjp.2022.42.
Wen J, Sawmiller D, Wheeldon B, Tan J. A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity. CNS Neurol Disord Drug Targets. 2019;18(10):769-778. doi: 10.2174/1871527318666191114095249. PMID: 31724518.
Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016 Dec;4(1):27. doi: 10.1186/s40345-016-0068-y. Epub 2016 Dec 17. PMID: 27900734; PMCID: PMC5164879.
Ferensztajn-Rochowiak E, Rybakowski JK. Long-Term Lithium Therapy: Side Effects and Interactions. Pharmaceuticals (Basel). 2023 Jan 3;16(1):74. doi: 10.3390/ph16010074. PMID: 36678571; PMCID: PMC9867198.
Baird-Gunning J, Lea-Henry T, Hoegberg LCG, et al. Lithium Poisoning. J Intensive Care Med. 2017 May;32(4):249-263. doi: 10.1177/0885066616651582. Epub 2016 Aug 11. PMID: 27516079.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Barbara Denys, Karolina Góra, Wojciech Zdziennicki, Patryk Zimnicki, Marta Lato, Konrad Iberszer, Maria Litwiniuk, Marcin Zaniuk, Kamil Hurkała, Dominika Antonik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 653
Number of citations: 0
